Yellow Fever in depth.

Overview

Yellow fever is an acute viral hemorrhagic disease caused by yellow fever virus (YFV) — a positive-sense single-stranded RNA virus of the genus Flavivirus in the family Flaviviridae (the same family as dengue, Zika, and West Nile virus). The virus is transmitted to humans through the bite of infected Aedes or Haemagogus mosquitoes in tropical Africa and South America. Yellow fever is named for the jaundice (yellowing of skin and eyes) that occurs in severe cases from virus-induced liver damage.

WHO estimates approximately 200,000 cases of yellow fever occur annually, causing approximately 30,000 deaths. Approximately 90% of cases occur in sub-Saharan Africa. The disease presents along a spectrum from mild fever to a devastating hemorrhagic illness with liver failure, renal failure, and bleeding — the so-called "toxic phase," with a case fatality rate of 20–50% in those who develop it.

One of the most significant facts about yellow fever is that it is entirely preventable with a single dose of the 17D live attenuated vaccine — one of the most effective vaccines ever developed, with >99% seroconversion and protection now considered lifelong. Yet despite this tool, yellow fever continues to cause significant mortality because immunization coverage remains incomplete in endemic areas, and outbreaks periodically occur in unvaccinated populations. The 2016 Angola/DRC outbreak — one of the largest in recent decades — infected thousands and threatened global spread through viremic travelers to countries with abundant Aedes aegypti mosquitoes but no yellow fever immunity.

History & Origin

Yellow fever originated in Africa and was introduced to the Americas through the transatlantic slave trade, where it caused devastating epidemics. The disease decimated colonial populations in the Caribbean and Americas in the 17th–19th centuries. The Philadelphia yellow fever epidemic of 1793 killed approximately 10% of the city's population. The opening of the Panama Canal was severely hampered by yellow fever (and malaria) deaths among workers — a problem eventually brought under control by Walter Reed's team after confirming mosquito transmission in 1900 (Cuba). William Gorgas subsequently implemented mosquito control measures that allowed the canal's completion.

Max Theiler developed the 17D live attenuated vaccine in 1937, for which he received the Nobel Prize in Physiology or Medicine in 1951. The 17D vaccine remains the mainstay of yellow fever prevention more than 85 years later — a testament to its effectiveness and safety.

Transmission

Three distinct transmission cycles of yellow fever virus exist, based on the mosquito species and host populations involved:

• Sylvatic (jungle/forest) cycle: Virus circulates between non-human primates (monkeys) and forest-dwelling Haemagogus (Americas) or Aedes africanus (Africa) mosquitoes. Humans are incidentally infected when entering forests — typically hunters, loggers, and forest workers.
• Intermediate (savannah) cycle: Occurs in Africa between humans and semi-domestic Aedes species in moist savannah areas bordering forests. This is the most common cycle causing most African yellow fever outbreaks.
• Urban cycle: Aedes aegypti transmits virus from human to human in urban settings — capable of explosive epidemics in unvaccinated populations. Urban yellow fever was eliminated from most of the Americas in the 20th century but remains a risk if adequate vaccination coverage is not maintained.

Yellow fever is not transmitted between people through contact, sneezing, coughing, or touching. An infected person is viremic and potentially infectious to mosquitoes for 5–7 days after symptom onset.

Symptom Timeline

The incubation period is 3–6 days after an infected mosquito bite. Most infections (approximately 80%) are mild or asymptomatic. About 15% develop the severe toxic phase.

Diagnosis

• RT-PCR: Detection of YFV RNA in serum — most sensitive in the first 3–5 days of illness (viremic phase). Reference standard for confirmation. Required for outbreak investigation.
• IgM/IgG serology (ELISA): YFV-specific IgM antibodies appear from day 5–7 of illness. IgM confirms recent infection. Cross-reactive antibodies with dengue, Zika, and other flaviviruses can cause false positives — plaque reduction neutralization testing (PRNT) is used for confirmation.
• Plaque Reduction Neutralization Test (PRNT): Gold standard for serological confirmation; distinguishes yellow fever from other flavivirus infections. Requires specialized laboratory.
• Liver function tests: Markedly elevated AST and ALT (often >1000 U/L in toxic phase); elevated bilirubin (jaundice); prolonged prothrombin time (coagulopathy).
• Urinalysis: Proteinuria and hematuria indicate renal involvement in severe disease.
• Full Blood Count: Leukopenia (low white cell count) in the acute phase; thrombocytopenia in severe disease.
• Travel history: Essential context — yellow fever should be considered in any febrile patient who visited an endemic area within 6 days of symptom onset.

Treatment

No specific antiviral treatment is approved for yellow fever. Management is supportive with intensive monitoring.

• Supportive care: Rest, hydration (oral or IV), paracetamol for fever and pain. NSAIDs and aspirin are contraindicated due to bleeding risk.
• ICU care for toxic phase: Strict fluid balance management; vasopressors for cardiovascular instability; blood transfusion and fresh frozen plasma for coagulopathy/bleeding; renal replacement therapy (dialysis) for kidney failure; mechanical ventilation if needed.
• Liver transplantation: Has been performed in a small number of severe yellow fever cases with acute liver failure, with variable outcomes.
• No treatment = Prevention: The critical message for yellow fever is that vaccination is the essential intervention. With a >99% effective, single-dose, lifelong vaccine available, no one in an endemic area should be unvaccinated.

Prevention & Vaccines

• 17D live attenuated vaccine: One of the most effective vaccines ever developed. A single dose provides >99% seroconversion and protection now considered lifelong by WHO (2016 IHR revision). The vaccine is recommended for all persons aged 9 months and older in endemic areas and travelers to endemic regions.
• International Certificate of Vaccination (ICVP / "Yellow Card"): Proof of yellow fever vaccination — legally required for entry to many endemic and some non-endemic countries. Valid for life under current WHO guidelines.
• WHO EYE (Eliminating Yellow fever Epidemics) Strategy: Launched in 2017 to vaccinate 1 billion people in 40 high-risk countries by 2026 through routine immunization and preventive mass vaccination campaigns.
• Mosquito protection: DEET repellents, long-sleeved clothing, bed nets — particularly important in endemic areas for travelers who cannot be vaccinated.
• Fractional dose vaccination: During the 2016 Angola/DRC outbreak, WHO authorized use of fractional doses (1/5 standard dose) to extend vaccine supply in emergency situations — providing adequate protection in the short term.

Global Impact

Yellow fever is endemic in 47 countries in Africa and Latin America, placing approximately 1 billion people at risk. WHO estimates approximately 200,000 cases and 30,000 deaths annually, with 90% of cases in Africa. The disease is massively underreported — actual case counts are estimated to be 10–250 times higher than officially reported.

The 2015–2016 Angola and DRC outbreak was a major global alert — Angola reported over 4,000 suspected cases and 374 deaths, with subsequent spread to DRC and exported cases detected in China (non-endemic country with no yellow fever vaccination program). The outbreak severely depleted the global WHO emergency vaccine stockpile, prompting authorization of fractional dosing and accelerated efforts to increase global manufacturing capacity.

Brazil experienced major yellow fever outbreaks in 2016–2018, with cases in previously non-endemic southeastern states including Sao Paulo, Minas Gerais, and Espirito Santo — raising concerns about re-urbanization of yellow fever transmission via Aedes aegypti. Over 2,100 confirmed cases and 723 deaths were recorded in Brazil during 2017–2019, including epizootics (monkey deaths) that served as early warning signals.

Country-Specific Information

Brazil: Brazil is a major yellow fever endemic country. The 2017–2019 outbreaks in southeastern Brazil — historically thought low-risk — killed over 700 people and prompted emergency vaccination campaigns. Brazil has successfully implemented reactive mass vaccination using fractional doses to protect tens of millions of people.

DRC: DRC has endemic yellow fever and regularly reports outbreaks, often overlapping with Ebola and other hemorrhagic fever outbreaks, complicating clinical diagnosis. Yellow fever vaccination is a recommended routine immunization for Congolese children.

Nigeria: Nigeria is the most populous yellow fever endemic country. Outbreaks occur regularly in northern states where routine vaccination coverage is lower. Nigeria demonstrated significant yellow fever deaths as recently as 2019–2022.

Angola: The 2016 Angola outbreak (epicenter: Luanda) was one of the largest urban yellow fever outbreaks in Africa in decades, triggering the global vaccination stockpile emergency response. Angola now has an expanded immunization programme for yellow fever.

Frequently Asked Questions

Sources & Citations

Related Diseases